NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

Centre for Health Technology Evaluation

# Technology Appraisal Committee A meeting minutes

**Minutes:** Confirmed

**Date and time:** 11 October 2022

**Location:** NICE London Office, 2 Redman Place, London E20 1JQ and via Zoom

## Attendees

Committee members present

1. Dr Jane Adam (Chair Topics 2 & 3) Present for all items
2. Dr James Fotheringham (Chair Topic 1) Present for all items
3. Dr Rada Todd (Future chair) Present for all items
4. Dr Peter Baker-Gulliver Present for all items
5. Richard Ballerand Present for all items
6. Dr Craig Buckley Present for all items
7. Dr Andrew Champion Present for all items
8. Ana Duarte Present for all items
9. Dr Steve Edwards Present for all items
10. Dr Lewis Choo Present for all items
11. Dr Fiona MacPherson Smith Present for all items
12. Professor G.J. Melendez-Torres Items 5 to 6.2.2
13. Dr Pratheeban Nambyiah Present for all items
14. Hugo Pedder Items 1 to 5.2.2
15. Becky Pennington Present for all items
16. Dominic Pivonka Present for all items
17. Dr Mohit Sharma Present for all items
18. Alan Thomas Present for all items
19. Min Ven Teo Items 1 to 4.2.2

NICE staff present

Janet Robertson, Associate Director Items 1 to 4.2.2 & 6 to 6.2.2

Henry Edwards, Associate Director Items 5 to 5.2.2

Thomas Feist, Project Manager Items 1 to 4.2.2 & 6 to 6.2.2

Jeremy Powell, Project Manager Items 1 to 5.2.2

Joanna Richardson, Heath Technology Assessment Adviser Items 1 to 4.2.2

Elizabeth Bell, Heath Technology Assessment Adviser Items 5 to 5.2.2

Zoe Charles, Heath Technology Assessment Adviser Items 6 to 6.2.2

Heather Stegenga, Heath Technology Assessment Analyst Items 1 to 4.2.2

Nigel Gumbleton, Heath Technology Assessment Analyst Items 5 to 5.2.2

Thomas Jarratt, Heath Technology Assessment Analyst Items 6 to 6.2.2

Adam Storrow, Business Analyst, RIA Present for all items

Sarah Bromley, Senior Medical Editor Items 1 to 4.2.2

Anna Sparshatt, Senior Medical Editor Items 5 to 5.2.2

Helen Barnett, Senior Medical Editor Items 6 to 6.2.2

Ella Fitzpatrick, Public Involvement Adviser, PIP Items 1 to 4.1.3 & 6 to 6.1.3

Laura Marsden, Public Involvement Adviser, PIP Items 5 to 5.1.3

Laura Kelly, Assistant Project Manager, COT Present for all items

Rosalee Mason, Coordinator, MIP Items 1 to 4.1.3 & 5 to 5.1.3 & 6 to 6.1.3

Lyn Davis, Coordinator, MIP Items 1 to 4.1.3 & 5 to 5.1.3 & 6 to 6.1.3

Gemma Smith, Coordinator, COT Present for all items

Marcia Miller, Administrator, TA Items 1 to 4.2.2 & 6 to 6.2.2

Mohammed Towhasir, Administrator, TA Items 5 to 5.2.2

NICE staff observers present

Ian Watson, Senior Technical Advisor, Methods Items 5 to 6.2.2

Oyewumi Afolabi, Technical Analyst, PASLU Items 1 to 4.1.3 & 5 to 5.2.2

Emily Eaton-Turner, Technical Analyst, Commercial Risk Assessment, Present for all items

Neha Jiandani, Technical Analyst, Commercial Liaison, Items 6 to 6.2.2

Stephen Norton, Technical Analyst, Managed Access, Items 5 to 6.2.2

Thomas Palmer, Technical Analyst, Managed Access, Items 6 to 6.2.2

Lewis Ralph, Heath Technology Assessment Analyst Items 1 to 5.2.2

Sharlene Ting, Heath Technology Assessment Analyst Items 5 to 5.1.3

Sarah Wilkes, Heath Technology Assessment Analyst Items 5 to 5.1.3

Emma Bajela, Associate Health Technology Assessment Analyst, Items 1 to 4.2.2

Harriet Edmondson, Public Health Registrar, Managed Access, Items 1 to 4.1.3 & 5 to 5.1.3

Georgina Fletcher, Media relations executive, External communications, Items 5 to 5.1.3 & 6 to 6.1.3

External assessment group representatives present

G.J Melendez-Torres, Peninsula Technology Assessment Group (Pen-TAG), Items 1 to 4.1.3

Brian O’Toole, Peninsula Technology Assessment Group (Pen-TAG), Items 1 to 4.1.3

Stephen Rice, Newcastle NIHR TAR Team, Newcastle University, Items 5 to 5.1.3

Katie Thomson, Newcastle NIHR TAR Team, Newcastle University, Items 5 to 5.1.3

Penny Whiting, Bristol Technology Assessment Group, University of Bristol, Items 6 to 6.1.3

Elsa Marques, Bristol Technology Assessment Group, University of Bristol, Items 6 to 6.1.3

Howard Thom, Bristol Technology Assessment Group, University of Bristol , Items 6 to 6.1.3

Clinical, Patient & NHS England experts present

Professor Peter Clark, Cancer Drug Fund Clinical Lead, NHS England, Present for all items

Dr Clare Green, Medical Oncologist, clinical expert nominated by Merck Sharp & Dohme, Items 1 to 4.1.3

Dr Susan Lalondrelle, Consultant Clinical Oncologist, clinical expert nominated by Peaches Womb Cancer Trust, Items 1 to 4.1.3

Grace Teeling, Patient expert nominated by Peaches Womb Cancer Trust, Items 1 to 4.1.3

Helen White, Patient expert nominated by Peaches Womb Cancer Trust, Items 1 to 4.1.3

Emma Fisher, Patient expert nominated by METUPUK, Items 5 to 5.1.3

Olga Oikonomidou, Senior Clinical Lecturer in Breast Cancer Medicine and Honorary Consultant Medical Oncologist, clinical expert nominated by NCRI-ACP-RCP-ACP, Items 5 to 5.1.3

Professor Peter Schmid, Centre Lead, Centre of Experimental Cancer Medicines, clinical expert nominated by Daiichi Sankyo UK, Items 5 to 5.1.3

Holly Heath, Patient expert nominated by Breast Cancer Now, Items 5 to 5.1.3 & 6 to 6.1.3

Stuart McIntosh, Clinical Reader in Surgical Oncology, clinical expert nominated by NCRI-ACP-RCP-RCR, Items 6 to 6.1.3

Melanie Sturtevant, Patient expert nominated by Breast Cancer Now, Items 6 to 6.1.3

Professor Andrew Tutt, Honorary Consultant Clinical Oncologist, clinical expert nominated by AstraZeneca UK, Items 6 to 6.1.3

## Minutes

### Introduction to the meeting

* 1. The chair Dr James Fotheringham welcomed members of the committee and other attendees present to the meeting.
  2. The chair noted apologies from Professor Abdallah Al-Mohammad, Dr David Maudgil, Dr Justin Daniels and Professor Khalida Ismail.

### News and announcements

* 1. The chair welcomed new committee member Louis Choo and returning member Becky Pennington welcomed back to committee. Committee also noted this would be our Chair Dr Jane Adams last meeting.

### Minutes from the last meeting

* 1. The committee approved the minutes of the committee meeting held on Tuesday 13 September 2022.

### Appraisal of pembrolizumab with lenvatinib for previously treated advanced, metastatic, or recurrent endometrial cancer [ID3811]

* 1. Part 1 – Open session
     1. The chair welcomed the invited experts, external assessment group representatives, members of the public and company representatives from MSD.
     2. The chair asked all committee members and experts, external assessment group representatives and NICE staff present to declare any relevant interests in relation to the item being considered.
* Nominated clinical expert Dr Susan Lalondrelle declared indirect interests as she is conducting research on the use of pembrolizumab for other treatment indications (endometrial and other cervix cancer). It was agreed her declaration would not prevent Dr Lalondrelle from providing expert advice to the committee.
* No further interests were declared for this appraisal
  + 1. The Chair led a discussion of the evidence presented to the committee. This information was presented to the committee by Dr Peter Baker-Gulliver, Ana Duarte, and Richard Ballerand.
  1. Part 2 – Closed session (company representatives, clinical and patient experts, external assessment group representatives and members of the public were asked to leave the meeting)
     1. The committee then agreed on the content of the Appraisal Consultation Document (ACD) or Final Appraisal Determination (FAD). The committee decision was reached by consensus.
     2. The committee asked the NICE technical team to prepare the Appraisal Consultation Document (ACD) or Final Appraisal Determination (FAD) in line with their decisions.
* Further updates will be available on the topic webpage in due course: <https://www.nice.org.uk/guidance/indevelopment/gid-ta10692>

### Appraisal of trastuzumab deruxtecan for treating HER2-positive unresectable or metastatic breast cancer after trastuzumab and a taxane [ID3909]

* 1. Part 1 – Open session
     1. The chair Dr Jane Adam welcomed the invited experts, external assessment group representatives, members of the public and company representatives from Daiichi Sankyo UK.
     2. The chair asked all committee members and experts, external assessment group representatives and NICE staff present to declare any relevant interests in relation to the item being considered.
* Committee member Becky Pennington declared financial interests as she has undertaken consultancy work funded by Roche (via the ABPI/office for health economics) and received a fee. This was in April 2022. The work was methodological relating the carers' HRQL and was not specific to any drug. The work was not related to breast cancer or trastuzumab emtansine. It was agreed her declaration would not prevent Becky from participating in discussions on this appraisal.
* Nominated patient expert Holly Heath declared indirect financial interests as in the last 12 months Breast Cancer Now has received funding from the manufacturer Daiichi Sankyo and possible comparator company Roche either towards their living with secondary breast cancer online and face to face services It was agreed that her declaration would not prevent Holly from providing expert advice to the committee.
* Nominated clinical expert Professor Peter Schmid declared indirect interests as he is conducting research on the use of pembrolizumab for other treatment indications (endometrial and other cervix cancer). It was agreed his declaration would not prevent Professor Peter Schmid from providing expert advice to the committee.
* No further interests were declared for this appraisal.
  + 1. The Chair led a discussion of the evidence presented to the committee. This information was presented to the committee by Dr Fiona MacPherson Smith and Dr Mohit Sharma.
  1. Part 2 – Closed session (company representatives, clinical and patient experts, external assessment group representatives and members of the public were asked to leave the meeting).
     1. The committee then agreed on the content of the Appraisal Consultation Document (ACD) or Final Appraisal Determination (FAD). The committee decision was reached by consensus.
     2. The committee asked the NICE technical team to prepare the Appraisal Consultation Document (ACD) or Final Appraisal Determination (FAD) in line with their decisions.
* Further updates will be available on the topic webpage in due course: <https://www.nice.org.uk/guidance/indevelopment/gid-ta10804>

### Appraisal of olaparib for adjuvant treatment of high-risk HER2-negative, BRCA-positive early breast cancer after chemotherapy [ID3893]

* 1. Part 1 – Open session
     1. The chair Dr Jane Adam welcomed the invited experts, external assessment group representatives, members of the public and company representatives from AstraZeneca UK Ltd.
     2. The chair asked all committee members and experts, external assessment group representatives and NICE staff present to declare any relevant interests in relation to the item being considered.
* Committee member Hugo Pedder declared non-financial professional & personal interests as he is a member of Bristol TAG with whom he has worked on this appraisal. As a direct conflict Hugo did not participate in discussions on this appraisal.
* Nominated patient experts Holly Heath and Melanie Sturtevant declared indirect financial interests as in the last 12 months Breast Cancer Now has received funding from the manufacturer AstraZeneca towards the Helpline. Breast Cancer Now funded researchers are involved in PARP inhibitor research. Breast Cancer Now receives from The Institute of Cancer Research (ICR) a share of royalties/payments from sales of olaparib by AstraZeneca and Merck. It was agreed that her declaration would not prevent Holly from providing expert advice to the committee.
* Nominated clinical expert Professor Andrew Tutt declare direct financial interests as he has received personal fees from several pharmaceutical companies and receives a share of royalties from ICR relating to sales of Olaparib and other PARP inhibitors, he also declared indirect interests as there have been payments to is institution for research and speaking. It was agreed his declarations would not prevent Professor Tutt from providing expert advice to the committee.
* No further interests were declared for this appraisal.
  + 1. The Chair led a discussion of the evidence presented to the committee. This information was presented to the committee by Alan Thomas and Dr Craig Buckley.
  1. Part 2 – Closed session (company representatives, clinical and patient experts, external assessment group representatives and members of the public were asked to leave the meeting).
     1. The committee then agreed on the content of the Appraisal Consultation Document (ACD) or Final Appraisal Determination (FAD). The committee decision was reached by consensus.
     2. The committee asked the NICE technical team to prepare the Appraisal Consultation Document (ACD) or Final Appraisal Determination (FAD) in line with their decisions.
* Further updates will be available on the topic webpage in due course: <https://www.nice.org.uk/guidance/indevelopment/gid-ta10903>.

### Date of the next meeting

The next meeting of the Technology Appraisal Committee A will be held via Zoom on Tuesday 8 November 2022 and will start promptly at 09.30.